If You Invested in Edwards Lifesciences Corp (EW)
Looking for the current price? See the EW quote & overviewWhat $1,000 or $10,000 in EW Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Nov 23, 2015 |
|---|---|---|---|---|
| $1,000 | $1,202 +20% | $887 -11% | $3,593 +259% | $3,795 +279% |
| $10,000 | $12,023 +20% | $8,869 -11% | $35,930 +259% | $37,947 +279% |
Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-11-20. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for EW$1,000 Investment Over Time
EW vs S&P 500Year-by-Year Returns
EW annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2015Nov 23 to Dec 31 | $26.84 | $26.33 | -1.9% | -1.9% |
| 2016 | $26.33 | $31.23 | +18.6% | +16.4% |
| 2017 | $31.23 | $37.57 | +20.3% | +40.0% |
| 2018 | $37.57 | $51.06 | +35.9% | +90.2% |
| 2019 | $51.06 | $77.76 | +52.3% | +189.7% |
| 2020 | $77.76 | $91.23 | +17.3% | +239.9% |
| 2021 | $91.23 | $129.55 | +42.0% | +382.7% |
| 2022 | $129.55 | $74.61 | -42.4% | +178.0% |
| 2023 | $74.61 | $76.25 | +2.2% | +184.1% |
| 2024 | $76.25 | $74.03 | -2.9% | +175.8% |
| 2025 | $74.03 | $85.25 | +15.2% | +217.6% |
| 2026Dec 31, 2025 to Nov 20 | $85.25 | $101.85 | +19.5% | +279.5% |
About Edwards Lifesciences Corp
Healthcare · NYSE
Edwards Lifesciences Corporation (NYSE: EW) is a medical technology company focused on structural heart disease. Classified under surgical appliance and supplies manufacturing, the company is described in its public materials as a global structural heart innovation company driven by a passion to improve patient lives. Its work centers on developing and commercializing heart valve and related therapies for patients with advanced stages of structural heart disease.
According to company disclosures and press releases, Edwards Lifesciences focuses on therapies for aortic stenosis (AS), mitral regurgitation (MR), tricuspid regurgitation (TR), pulmonic disease, aortic regurgitation (AR) and structural heart failure. The company highlights a long history in heart valve innovation, referencing more than 65 years of leadership and valve expertise in its communications. Edwards Lifesciences’ common stock trades on the New York Stock Exchange under the symbol EW.
Core structural heart focus
Edwards Lifesciences describes itself as a structural heart innovation company that develops technologies and evidence to transform care for patients with valvular and related heart disease. Its communications emphasize a portfolio of transcatheter and surgical therapies addressing aortic, mitral, tricuspid and pulmonic valves, as well as emerging areas such as structural heart failure and transcatheter aortic valve replacement for aortic regurgitation (TAVR‑AR).
The company’s transcatheter aortic valve replacement (TAVR) platform, branded SAPIEN, is repeatedly cited in clinical and investor materials. Edwards states that SAPIEN has become a global benchmark for TAVR and notes that it is the most studied valve platform, with more than 15 years of clinical trials, multiple publications in major medical journals and a large number of patients treated worldwide. Data from the PARTNER trial series, including long‑term follow‑up, are used by the company to support the durability and performance of the SAPIEN 3 valve compared with surgical aortic valve replacement.
Transcatheter mitral and tricuspid therapies (TMTT)
In its public updates, Edwards Lifesciences describes a transcatheter mitral and tricuspid therapies (TMTT) portfolio that includes repair and replacement technologies. Named systems in company news releases include the PASCAL mitral valve repair system, the EVOQUE tricuspid valve replacement system and the SAPIEN M3 transcatheter mitral valve replacement (TMVR) system. The company reports that these therapies are intended for patients with complex mitral and tricuspid disease, many of whom have limited or no other treatment options.
Edwards has highlighted pivotal clinical data such as the ENCIRCLE trial for SAPIEN M3 and registry data for the EVOQUE tricuspid valve. The company states that these data demonstrate high rates of regurgitation reduction, safety outcomes and improvements in symptoms and quality of life in patient populations deemed unsuitable for other interventions. Edwards also notes that the SAPIEN M3 system has received regulatory approvals in certain markets and that its portfolio of transcatheter mitral and tricuspid therapies is expanding with next‑generation systems and additional indications, as described in its investor conference materials.
Surgical heart valve and cardiac surgery portfolio
Alongside transcatheter therapies, Edwards Lifesciences communicates an ongoing focus on surgical heart valve therapies. The company refers to its RESILIA tissue technology and associated platforms such as INSPIRIS, MITRIS and KONECT in its investor presentations and earnings releases. It states that these surgical innovations are intended to address critical unmet needs in cardiac surgery and to support patients best treated with surgical procedures, including complex and concomitant operations.
Edwards also references plans for additional surgical products, such as TRIFORMIS, described in company communications as a surgical valve designed for the tricuspid position. These references illustrate the company’s strategy of maintaining a presence in both transcatheter and surgical segments of structural heart therapy.
Emerging areas: structural heart failure and AR
In its investor conference materials, Edwards Lifesciences identifies structural heart failure and transcatheter treatment of aortic regurgitation as emerging therapeutic areas. The company describes plans to develop implantable pressure sensor–guided management solutions for heart failure and to advance TAVR‑AR as a new frontier in aortic valve disease treatment. It characterizes aortic regurgitation as a deadly, progressive disease with limited treatment options and presents itself as aiming to lead AR therapy through novel transcatheter valve technologies and clinical trials.
Edwards has also reported that it sought to acquire JenaValve Technology, a company associated with AR therapy, but an injunction granted to the U.S. Federal Trade Commission blocked the proposed acquisition. In an 8‑K filing and related press release, Edwards stated that, as a result, it would not acquire JenaValve and that it would continue to advance its own AR therapy programs, including the SOJOURN transcatheter AR valve and the JOURNEY pivotal trial.
Clinical evidence and partnerships
Across multiple press releases and conference summaries, Edwards Lifesciences emphasizes the role of clinical evidence in its business. The company highlights late‑breaking trial presentations at major cardiology meetings, including Transcatheter Cardiovascular Therapeutics (TCT), and publications in journals such as The New England Journal of Medicine and The Lancet. It points to long‑term outcomes data from the PARTNER trial series, the ENCIRCLE TMVR trial, and real‑world registries for EVOQUE as examples of evidence supporting its therapies.
Edwards also describes partnerships with clinicians, health systems and professional organizations. For example, it has announced founding sponsorship of the American Heart Association’s Heart Valve Initiative, which focuses on improving care and outcomes for patients with heart valve disease through guideline‑based care, data collection, certification programs and education. The company portrays these collaborations as aligned with its patient‑focused culture.
Investor communications and capital markets activity
Edwards Lifesciences regularly issues earnings releases and hosts conference calls to discuss financial results and outlook. In its 8‑K filings, the company reports quarterly sales by product group, adjusted earnings per share guidance and other financial metrics, while noting that certain figures are presented on a non‑GAAP basis. It also discloses activities such as accelerated share repurchase agreements and share repurchase authorizations approved by its board of directors.
The company participates in major healthcare investment conferences, such as the J.P. Morgan Healthcare Conference, where it presents its strategy and financial guidance. In these forums, Edwards describes its structural heart portfolio, growth expectations for TAVR, TMTT and surgical product groups, and its intention to continue investing in research and development for structural heart therapies.
Headquarters and corporate structure
Edwards Lifesciences Corporation is incorporated in Delaware and lists its principal executive offices in Irvine, California, in its SEC filings. The company’s common stock, with a par value of $1.00 per share, is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on the New York Stock Exchange under the symbol EW.
Position within the medical device industry
Within the broader medical device and manufacturing sector, Edwards Lifesciences is categorized under surgical appliance and supplies manufacturing. Its public statements consistently describe the company as a global structural heart innovation company with therapies across transcatheter and surgical modalities. The firm’s focus on structural heart disease, heart valve therapies and related technologies distinguishes it within this industry classification.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Edwards Lifesciences Corp investment returns
How much would $1,000 invested in Edwards Lifesciences Corp be worth today?
If you invested $1,000 in Edwards Lifesciences Corp (EW) 10 years ago on 2016-11-22, your investment would be worth $3,593 as of 2026-11-20, a +259.3% price return without dividends, growing at a compounded rate of 13.7% per year (CAGR).
Has Edwards Lifesciences Corp outperformed the S&P 500?
Over the past 10 years, EW returned +259.3% compared to +212.7% for the S&P 500, outperforming the benchmark by 46.6 percentage points.
What is Edwards Lifesciences Corp's average annual return?
The compound annual growth rate (CAGR) of EW’s share price over the past 10 years is 13.7%, without dividends. Individual years vary a great deal, and EW’s best recent full year was 2019 (+52.3%) while the worst was 2022 (-42.4%).
For informational and educational purposes only, not investment advice.